Just as a followup, there are currently 11 studies involving Sipuleucel-T that are getting underway. 8 of those are actively recruiting, the other 3 should be starting soon. 4 of these studies are not sponsored by DNDN. 1 of the studies that is recruiting is related to Europe Manufacturing QA/QC.
I think it was mostly shorts covering. I think that more covering will take place leading up to May 9th conference call. I don't think they want to be short in the event that the call is good news. If the call is bad news, then expect them to short some more. But there have been some good things coming out. There are 4 clinical trials that just started looking at Provenge where the sponsors are NOT Dendreon. I think that bodes well for Provenge as the private and public research community is taking the drug seriously as these trials are not cheep to run.
selling after a 5.5% gain is chump change. shorts realize this may be the bottom and the more shorts cover the more shorts will join in covering and before you know it - it's a multi-day short squeeze to $10